denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: ASH Poster Walks
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, patient-reported outcomes, real-world evidence, Adverse Events, survivorship
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, patient-reported outcomes, real-world evidence, Adverse Events, survivorship
Thursday, December 14, 2023: 5:00 PM-6:00 PM
(Virtual Program)
One unifying thread across classical and malignant hematology involves efforts to reduce "time toxicity." While specific definitions of time toxicity are still being established, the broad principle is clear: particularly for incurable diseases, patients often spend significant proportions of their days on healthcare-related interactions. While studies of reduced-frequency romiplostim in immune thrombocytopenic purpura (ITP) or teclistamab in myeloma clearly fit this definition, for example, so too do trials that seek to reduce transfusion dependence in myeloproliferative neoplasms (MPN) or lower the frequency of pain crises requiring Emergency Room visits in sickle-cell disease. Relevant studies also include interventions of decreased diagnostic monitoring and digital health tools to decrease patient time in clinic without compromising clinical outcomes. A concerted cross-disease poster walk focused on "time toxicity" will help the field understand how to define this concept broadly, how to design studies that address time toxicity (either directly through medication dosing frequency or indirectly by reducing healthcare resource utilization) and exploring the impact of time toxicity on patient quality of life.
See more of: ASH Poster Walks